Establishment Labs (NASDAQ:ESTA) Posts Quarterly Earnings Results, Misses Expectations By $0.34 EPS

Establishment Labs (NASDAQ:ESTA) issued its quarterly earnings data on Wednesday. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34), Zacks reports. The company had revenue of $44.51 million for the quarter, compared to analyst estimates of $44.45 million. Establishment Labs had a negative return on equity of 184.55% and a negative net margin of 46.13%.

Establishment Labs Stock Performance

Shares of NASDAQ ESTA opened at $38.57 on Thursday. The stock has a market capitalization of $1.08 billion, a PE ratio of -15.11 and a beta of 1.12. Establishment Labs has a 52 week low of $28.16 and a 52 week high of $60.12. The stock has a 50 day moving average price of $37.50 and a 200 day moving average price of $41.37. The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62.

Wall Street Analysts Forecast Growth

Separately, Stephens upgraded Establishment Labs to a “strong-buy” rating in a report on Monday, December 2nd. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Establishment Labs currently has a consensus rating of “Buy” and a consensus price target of $60.60.

About Establishment Labs

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.